Topics covered include are payers helping or hindering biosimilar market access as well as can MCDA ...
Read moreBiosimilars have the potential to be considered comparable to generics and offer healthcare benefits...
Read moreIn this issue is an overview of the future changes to the UK Cancer Drug Fund as well as approaches ...
Read moreThis study determines if EU pricing and reimbursement bodies have revised their pricing and reimburs...
Read moreEuropean payers have not considered biosimilars to be comparable to their reference products or full...
Read moreThis issue includes topics such as the recent AIFA approval of Avastin for off label use in Wet-AMD ...
Read moreA recent Biosimilar pricing announcement of 72% discount of an anti-tumour necrosis factor blows con...
Read moreNICE revises biosimilars guidance to conclude that they do not believe that biosimilars are identica...
Read moreIncluding Sovaldi's $84,000 price, adaptive licence pilots from the EMA and is 2015 a turning point ...
Read more